Judah Frommer, an analyst from Morgan Stanley, maintained the Buy rating on Bicara Therapeutics Inc.. The associated price target remains the same with $36.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Judah Frommer has given his Buy rating due to a combination of factors related to Bicara Therapeutics’ recent data release. The ESMO Asia abstract provided an update on the low dose of ficera in combination with pembro for HPV-negative 1L R/M HNSCC, which showed promising safety and efficacy results. The data from the Phase 1b study, involving 30 efficacy-evaluable patients, demonstrated outcomes consistent with the higher dose, suggesting that ficera could significantly enhance the standard of care in this patient population.
Frommer’s optimism is further supported by the comparable safety profile of the 750mg dose to the previously reported 1500mg dose, with no Grade 4 treatment-related adverse events and only one Grade 5 event attributed to pembro. The objective response rate and disease control rate were also favorable, reinforcing confidence in the drug’s potential. These factors collectively contribute to the positive outlook for Bicara Therapeutics and justify the Buy rating.
In another report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $36.00 price target.